Journal
VACCINES
Volume 1, Issue 3, Pages 328-342Publisher
MDPI AG
DOI: 10.3390/vaccines1030328
Keywords
HIV; vaccine; HIV-1 Gag; IgG antibody diversification; IgG subclasses
Categories
Funding
- National Health and Medical Research Council of Australia [510448]
- Medical Research Foundation of Royal Perth Hospital
Ask authors/readers for more resources
The development of vaccines to treat and prevent human immunodeficiency virus (HIV) infection has been hampered by an incomplete understanding of protective immune responses against HIV. Natural control of HIV-1 infection is associated with T-cell responses against HIV-1 Gag proteins, particularly CD8+ T-cell responses restricted by protective HLA-B alleles, but other immune responses also contribute to immune control. These immune responses appear to include IgG antibodies to HIV-1 Gag proteins, interferon-. -dependant natural killer (NK) cell responses and plasmacytoid dendritic cell (pDC) responses. Here, it is proposed that isotype diversification of IgG antibodies against HIV-1 Gag proteins, to include IgG2, as well as IgG3 and IgG1 antibodies, will broaden the function of the antibody response and facilitate accessory cell responses against HIV-1 by NK cells and pDCs. We suggest that this should be investigated as a vaccination strategy for HIV-1 infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available